Key facts
- This page summarizes Aron R. English's Form 4 filing for Anebulo Pharmaceuticals, Inc. (ANEB).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 26 Dec 2024, 16:15.
Aron R. English - 23 Dec 2024 Form 4 Insider Report for Anebulo Pharmaceuticals, Inc. (ANEB)
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- ANEB
- Reported as of
- 23 Dec 2024
- Net transaction value
- +$10,000,000
- SEC form
- 4
- Accepted by SEC
- 26 Dec 2024, 16:15:08 UTC
- Prior SEC filing
- 20 Dec 2024
- Next SEC filing
- 03 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Aron R. English
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Aron R. English filed Form 4 for Anebulo Pharmaceuticals, Inc. (ANEB) on 26 Dec 2024.
Change
- Previous filing in this sequence was filed on 20 Dec 2024.
- Current net transaction value: +$10,000,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ANEB
transaction
Common Stock
Purchase
- Transaction value
- $10,000,000
- Shares
- +10,101,010
- Change %
- +188%
- Price
- $0.9900
- Shares after
- 15,467,300
- Date
- 23 Dec 2024
- Ownership
- 22NW Fund, LP
- Footnotes
- F1, F2, F3
ANEB
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 4,654,528
- Date
- 23 Dec 2024
- Ownership
- Pharma Investors, LLC
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The shares were issued to 22NW Fund, LP in connection with a private placement offering of the Issuer.
Footnote F2
This Form 4 is filed jointly by Aron R. English and 22NW Fund, LP (collectively, the "Reporting Persons"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that collectively beneficially owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities of the Issuer owned directly by other members of the Section 13(d) group and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 or for any other purpose. Further, each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
Footnote F3
Securities owned directly by 22NW Fund, LP. Mr. English, as the Manager of 22NW Fund GP, LLC, which is the General Partner of 22NW Fund, LP, may be deemed to beneficially own the securities owned directly by 22NW Fund, LP.
Footnote F4
Securities owned directly by Pharma Investors, LLC. Mr. English, as the owner of Pharma Investors, LLC, may be deemed to beneficially own the securities owned directly by Pharma Investors, LLC.